ClinicaSpace.com
Clinical Research
News & Careers
 
Search the Site
    
 
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   


By Industry | By Industry Segment | By Services and Suppliers | By Location | Profile Search
 Company Profile

 

Idenix Pharmaceuticals, Inc. 

Corporate Headquarters
60 Hampshire Street
Cambridge  Massachusetts  02139  U.S.A.
Phone: 617-995-9800 Fax: 617-995-9801


SEARCH JOBS
Idenix Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix's current focus is on the treatment of infections caused by hepatitis C virus. Idenix is advancing a robust product pipeline in HCV treatment with programs in four different HCV drug classes. The company’s clinical candidates include IDX184, a liver-targeted nucleotide polymerase inhibitor, IDX320, a protease inhibitor and IDX375, a non-nucleoside polymerase inhibitor. Idenix also has a preclinical NS5A inhibitor program. Idenix believes that the future of HCV treatment will include novel combinations of direct-acting antivirals (DAAs) which could eliminate the need for interferon and/or ribavirin. The company’s goal is to develop low dose, once- or twice-daily agents with broad genotypic activity, a low potential for drug-drug interaction and that are designed for use in multiple combination regimens. With programs that span the major HCV drug classes, Idenix is well positioned to build a combination drug development strategy, both internally and with partners, to advance the future HCV paradigm.

 Key Statistics


Email:
Ownership: Public

Web Site: Idenix Pharmaceuticals, Inc.
Employees: 200 + worldwide
Symbol: IDIX
 









 Company News
Idenix Pharmaceuticals, Inc. (IDIX)'s "Good" News Shows Hep C Drug Market Increasingly Murky For Investors 4/9/2014 6:05:01 AM    More...
Idenix Pharmaceuticals, Inc. (IDIX) Announces Promising Clinical Data And Continued Progress In Nucleotide Prodrug Development Programs For The Treatment Of Hepatitis C 4/7/2014 9:29:00 AM    More...
Idenix Pharmaceuticals, Inc. (IDIX) Intends To Appeal Norway District Court Decision Regarding Patent Invalidity Case 3/24/2014 9:04:29 AM    More...
Idenix Pharmaceuticals, Inc. (IDIX) Announces Nucleotide Prodrug (IDX21437) And NS5A Inhibitor (Samatasvir) Poster Presentations At 49th Annual Meeting Of The European Association For The Study Of The Liver 3/24/2014 8:53:52 AM    More...
Idenix Pharmaceuticals, Inc. (IDIX) Files Patent Infringement Lawsuits Against Gilead Sciences, Inc. (GILD) In Europe 3/14/2014 9:27:24 AM    More...
Idenix Pharmaceuticals, Inc. (IDIX) Reports Fourth Quarter And Year Ended 2013 Financial Results 2/28/2014 9:24:24 AM    More...
Idenix Pharmaceuticals, Inc. (IDIX) To Present At Two Upcoming Healthcare Conferences 2/26/2014 9:03:57 AM    More...
Idenix Pharmaceuticals, Inc. (IDIX) To Present At The 2014 Leerink Swann and Company Global Healthcare Conference 2/7/2014 9:06:12 AM    More...
Idenix Pharmaceuticals, Inc. (IDIX) Announces Decision By The United States Patent And Trademark Office Patent Trial And Appeal Board In The First Patent Interference 1/30/2014 8:54:47 AM    More...
Idenix Pharmaceuticals, Inc. (IDIX) Eyes $106.7 Million Through Registered Direct Offering 1/28/2014 7:39:52 AM    More...
12345678910...